Akeso’s lung cancer drug shows 34% reduction in death risk

🔑 Enhanced Key Takeaways

•Ivonescimab is a first-in-class bispecific antibody that simultaneously targets both programmed death-1 (PD-1) and vascular endothelial growth factor A (VEGF-A), representing a novel dual-target approach in immuno-oncology.
•The HARMONi-6 trial, conducted in China, specifically compared ivonescimab plus chemotherapy against tislelizumab (a PD-1 inhibitor) plus chemotherapy, demonstrating ivonescimab's superiority in overall survival.
•The overall survival benefit of ivonescimab plus chemotherapy was consistent across various patient subgroups in the HARMONi-6 trial, including those with low (PD-L1 TPS <1%) or high (PD-L1 TPS ≥1%) PD-L1 expression.
•Ivonescimab received its initial marketing authorization in China in May 2024 for other non-small cell lung cancer (NSCLC) indications, including as a monotherapy for first-line PD-L1-positive advanced NSCLC and in combination with chemotherapy for EGFR-mutated NSCLC patients who progressed after TKI therapy.
•Summit Therapeutics holds the license for ivonescimab in several territories outside China, including the United States and Europe, and has submitted a Biologics License Application (BLA) to the FDA for an NSCLC indication, with a Prescription Drug User Fee Act (PDUFA) goal date of November 14, 2026.

📊 Competitor Analysis▸ Show

Feature/Benchmark	Ivonescimab (Akeso/Summit Therapeutics)	Tislelizumab (BeOne Medicines/BeiGene)	Other Emerging PD-1/VEGF Bispecifics (e.g., BioNTech/BMS's Pumitamig, Pfizer's PF-08634404)
Drug Class	First-in-class PD-1/VEGF Bispecific Antibody	Anti-PD-1 Monoclonal Antibody	PD-1/VEGF Bispecific Antibodies
Target(s)	PD-1 and VEGF-A (dual blockade)	PD-1	PD-1 and VEGF (dual blockade)
Efficacy (HARMONi-6, 1L sq-NSCLC + Chemo)	Median OS: 27.9 months; 34% reduction in death risk vs. control (HR=0.66); 24-month OS rate: 64.7%	Median OS: 23.7 months; 24-month OS rate: 48.6%	Early Phase II data for Pumitamig shows 70% ORR in 1L advanced NSCLC + chemo; Pfizer's PF-08634404 monotherapy showed 67.6% ORR in PD-L1+ advanced NSCLC.
Approval Status (for NSCLC)	Approved in China for multiple NSCLC indications (May 2024); BLA accepted by US FDA for EGFR-mutated non-squamous NSCLC (Jan 2026), PDUFA Nov 2026.	Approved in China for 1L NSCLC.	Investigational, in Phase II/III clinical trials.
Key Differentiator	Simultaneous dual blockade of immune checkpoint and angiogenesis pathways, showing superior OS over a PD-1 inhibitor in a head-to-head Phase III trial.	Standard PD-1 immune checkpoint inhibition.	Also dual-targeting, but clinical data for advanced squamous NSCLC is less mature compared to ivonescimab's HARMONi-6 results.

🛠️ Technical Deep Dive

Ivonescimab is a humanized, tetravalent Fc-silent bispecific monoclonal antibody.
It is engineered to simultaneously target programmed death-1 (PD-1) and vascular endothelial growth factor A (VEGF-A).
The dual mechanism of action involves:
- PD-1 blockade: It targets the PD-1 receptor on activated T cells, disrupting the PD-1/PD-L1 axis to reactivate cytotoxic T-cells and restore anti-tumor immune response.
- VEGF-A inhibition: It blocks VEGF-A, which is crucial for tumor angiogenesis (new blood vessel formation) and can also contribute to an immunosuppressive tumor microenvironment. By inhibiting VEGF-A, ivonescimab impairs tumor vascularization and enhances immune cell infiltration.
The tetravalent structure facilitates cooperative binding, where the presence of VEGF can enhance ivonescimab's binding affinity to PD-1, and vice-versa, leading to increased potency in blocking both pathways.
It contains Fc-silencing mutations to abrogate FcγRI/IIIa binding, which is associated with reduced antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) activities, and cytokine release, contributing to a manageable safety profile.

🔮 Future ImplicationsAI analysis grounded in cited sources

Ivonescimab is poised to become a new standard of care for first-line advanced squamous NSCLC globally.

The HARMONi-6 trial demonstrated a statistically significant and clinically meaningful overall survival benefit over an established PD-1 inhibitor plus chemotherapy, setting a new benchmark for treatment efficacy in this difficult-to-treat cancer.

The success of ivonescimab could validate the bispecific antibody approach for other difficult-to-treat cancers and accelerate their development.

Akeso is already investigating ivonescimab in multiple other solid tumors, including biliary-tract cancer, triple-negative breast cancer, and colorectal cancer, leveraging its dual-target mechanism that has shown promising results in NSCLC.

⏳ Timeline

2012

Akeso Inc. founded

2022-12

Summit Therapeutics partners with Akeso to license ivonescimab (SMT112) for territories outside China

2024-05

Ivonescimab receives first approval in China for EGFR-mutated locally advanced or metastatic non-squamous NSCLC

2025-04

HARMONi-6 Phase III trial (in China) met its primary endpoint of progression-free survival (PFS)

2026-01

US FDA accepted Biologics License Application (BLA) for ivonescimab in EGFR-mutated non-squamous NSCLC

2026-05

HARMONi-6 Phase III trial overall survival (OS) results presented at ASCO, showing 34% reduction in death risk

Akeso’s lung cancer drug shows 34% reduction in death risk

⚡ 30-Second TL;DR

Key Points

🧠 Deep Insight

🔑 Enhanced Key Takeaways

🛠️ Technical Deep Dive

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline

📎 Sources (23)

👉Related Updates